Concepedia

Salah Nabhan

SN

Statistics

Publications

9

Citations

447

H-Index

9

Active since

2012

Affiliations

Massachusetts General Hospital(Current)

Agios Pharmaceuticals (United States)

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Vanderbilt University Medical Center

Salah Nabhan is an author at Massachusetts General Hospital specializing in medicine, oncology, and hematologic malignancy therapy.

Publications per year

2012–2025

9

Publications

9

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi et al. · Blood · 2020 · 233 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi et al. · Blood · 2018 · 61 citations

Medicine, Oncology, Pharmacotherapy +13

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial

Mrinal M. Gounder, Melissa L. Johnson, Rebecca S. Heist et al. · Nature Communications · 2025 · 34 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects

David L. Dai, Hua Yang, Salah Nabhan et al. · European Journal of Clinical Pharmacology · 2019 · 30 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

Eytan M. Stein, Courtney D. DiNardo, Alice S. Mims et al. · Blood · 2017 · 25 citations

Medicine, Oncology, Pharmacology +11

1–5 of 9